Technical Analysis for CYTX - Cytori Therapeutics Inc

Grade Last Price % Change Price Change
grade F 0.28 12.90% 0.03
CYTX closed up 12.9 percent on Monday, March 18, 2019, on 3.67 times normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical CYTX trend table...

Date Alert Name Type % Chg
Mar 18 50 DMA Resistance Bearish 0.00%
Mar 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Mar 18 Crossed Above 20 DMA Bullish 0.00%
Mar 18 Pocket Pivot Bullish Swing Setup 0.00%
Mar 18 Volume Surge Other 0.00%
Mar 18 Wide Range Bar Range Expansion 0.00%
Mar 18 Above Upper BB Strength 0.00%
Mar 18 Upper Bollinger Band Touch Strength 0.00%
Mar 15 20 DMA Resistance Bearish 12.90%
Mar 15 Pocket Pivot Bullish Swing Setup 12.90%

Older signals for CYTX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cytori Therapeutics, Inc., a cell therapy company, engages in developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular diseases and other medical conditions. It primarily provides the Celution System, which automates the process of digesting fat tissue, releasing the ADRCs. It also offers the StemSource Cell Bank, a suite of products to allow hospitals or tissue banks to cryopreserve adipose-derived stem and regenerative cells; and StemSource 900/MB, a research laboratory equipment, as well as a range of ancillary products designed to optimize tissue harvest and graft delivery. Its products also include Celution 800 System that has CE Mark approval for certain soft tissue procedures, such as breast reconstruction, tissue ischemia, deficiency or injury of skin, fat, and muscle and fascia, as well as soft tissue wounds or fistulae associated with trauma, diabetes, ischemia, and radiation injury. The company markets its systems, instrumentations, and consumables directly, as well as through a network of distributors to hospitals, plastic surgery clinics, tissue banks, and stem cell banking companies, as well as researchers performing investigator-initiated and funded studies worldwide. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.
Biotechnology Biology Diabetes Nature Stem Cells Radiation Cell Biology Ancillary Products Cardiovascular Diseases Cell Therapy Injury Plastic Surgery Stem Cell Therapy Connective Tissue Deficiency Amniotic Stem Cell Bank Breast Reconstruction Ingeneron Radiation Injury
Is CYTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.3
52 Week Low 0.22
Average Volume 549,267
200-Day Moving Average 0.6303
50-Day Moving Average 0.284
20-Day Moving Average 0.2521
10-Day Moving Average 0.245
Average True Range 0.0231
ADX 12.6
+DI 33.2194
-DI 21.069
Chandelier Exit (Long, 3 ATRs ) 0.2307
Chandelier Exit (Short, 3 ATRs ) 0.2893
Upper Bollinger Band 0.2773
Lower Bollinger Band 0.2269
Percent B (%b) 1.05
BandWidth 19.992067
MACD Line -0.0085
MACD Signal Line -0.0127
MACD Histogram 0.0042
Fundamentals Value
Market Cap 9.72 Million
Num Shares 34.7 Million
EPS -1.00
Price-to-Earnings (P/E) Ratio -0.28
Price-to-Sales 1.71
Price-to-Book 1.28
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.36
Resistance 3 (R3) 0.35 0.33 0.34
Resistance 2 (R2) 0.33 0.31 0.33 0.34
Resistance 1 (R1) 0.30 0.30 0.32 0.31 0.33
Pivot Point 0.28 0.28 0.28 0.28 0.28
Support 1 (S1) 0.25 0.26 0.27 0.26 0.23
Support 2 (S2) 0.23 0.25 0.23 0.22
Support 3 (S3) 0.20 0.23 0.22
Support 4 (S4) 0.21